Skip to main content
Swing Capital

Mangalam Drugs and Organics Ltd

NSE: MANGALAM BSE: 532637Pharma

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]

₹29.2
52W: ₹22.7 — ₹95
PE 0 · Book ₹65.3 · -55% vs book
Market Cap₹46.3 Cr
Stock P/E—Price to Earnings
ROCE14%Return on Capital
ROE34.8%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Stock is trading at 0.47 times its book value

Weaknesses

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -9.39% over past five years.
  • −Promoter holding is low: 35.6%
  • −Company has a low return on equity of -11.0% over last 3 years.
  • −Contingent liabilities of Rs.34.6 Cr.
  • −Debtor days have increased from 45.3 to 63.4 days.
  • −Promoter holding has decreased over last 3 years: -14.7%

Shareholding Pattern

Promoters35.65%
FIIs0.32%
DIIs0%
Public64.03%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters50.31%50.3%▼0.050.3%50.3%50.3%50.3%35.64%▼14.735.65%▲0.0
FIIs0.21%0.11%▼0.10.11%0.47%▲0.40.53%▲0.10.11%▼0.40.13%▲0.00.32%▲0.2
DIIs0%0%0%0%0%0%0%0%
Public49.47%49.58%▲0.149.58%49.23%▼0.449.16%▼0.149.57%▲0.464.22%▲14.664.03%▼0.2

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales971027780897357505867
Expenses90916871806362526073
Operating Profit71289910-5-3-2-5
OPM %7%11%11%11%10%14%-8%-6%-3%-8%
Net Profit043310-14-7-10-13
EPS ₹0.322.241.691.70.880.09-8.67-4.58-6.18-8.25

AI Insights

Revenue Trend

Mar 2026 revenue at ₹232Cr, down 27% YoY. OPM at -6%.

Debt Position

Borrowings at ₹105Cr. Debt-to-equity ratio: 1.21x. High leverage — monitor closely.

Institutional Flow

DIIs: 0% (+0.00pp change). FIIs: 0.32% (+0.22pp change). Promoters hold 35.65%.

Margin & Efficiency

ROCE declining from 16% (Mar 2015) to -14% (Mar 2026). Working capital days: -54.

Recent Announcements